Antitumor
There is notable anticancer therapeutic potential for actinomycetes, especially those
whose products are associated with minimal side effects compared to conventional
chemotherapy, for instance the compound salinosporamide A [127].These hybrid BGCs and CGCs are prospective sources of novel secondary metabolites and
chemotherapeutic agents for pharmaceuticals.Marine actinomycin compounds with antitumor potential include
streptochlorin, actinofuranones, aureoverticillactam, chalocomycin B, cyanosporasides,
komodoquinones, nonactin, resitoflavine, sporolides, tetracenomycin D, thiocoraline, t-
muurolol, butenolides, echinosporins, and streptokordin.Ketomycin suppressed cellular migration and invasion in breast carcinoma cells,
inhibited NF-?B activity used in upstream signaling by hindering the autophosphorylation
of IKK-?/IKK-?, and minimized the 3D-invasion of breast carcinoma cells at nontoxic
concentrations [130]. Important secondary metabolites
from marine actinomycetes with antitumor potential include streptopyrrolidine, cyclo-(L-
Pro-L-Met), streptochlorin, lynamicins, marizomib, and thiocoraline [128].Two examples
of novel anticancer metabolites are the compound extracts ULDF4 and ULDF5 derived
from Streptomyces strains found at Lagos.These drugs were obtained from
Streptomyces verticillus, Streptomyces peucetius, Streptomyces caespitosus, and other intra-
generic isolates [107].